APHYQ: Bankruptcy PLAN effective. All shares cancelled.

http://otce.finra.org/DLDeletions

Reorganisation Filing with the NVSOS
Looks like a huge R/S (whipe-out) will take place
Reorganization
Document Number: 20150170936-34 # of Pages: 340
File Date: 4/15/2015

Previous Stock Value:
Par Value Shares: 100,000,000 Value: $ 0.001
Par Value Shares: 5,000,000 Value: $ 0.001
No Par Value Shares: 0
Total Authorized Capital: $ 105,000.00

New Stock Value:
Par Value Shares: 1,000 Value: $ 0.001
No Par Value Shares: 0
Total Authorized Capital: $ 1.00

http://nvsos.gov/sosentitysearch/corpActions.aspx?lx8nvq=sNjwcMtGI6d0yOvra9eTew%253d%253d&CorpName=ASSURED+PHARMACY%2c+INC.

APHYQ - I am a shareholder, yet I have not received the letter. I checked with a prior address, and they have not received a letter either. Was it by FedEx, UPS, or USPS?

Has anyone else not received the letter?

So how do you interpret the letter?

Yes. What does it all mean?

APHYQ - Which letters? From the lawyers?

Does anyone understand what these letters mean?

Has any body talked to Robert recently?

Yes, Please elaborate if you do get some info... I have sold a few shares but plan on hold a bit longer to see what will come of this letter.... I would think at least a $0.20 per share compensation should make everybody happy! Good luck to all....

APHYQ - There is a letter that shareholders should/could have received from a lawyer. I have not seen the letter as of yet. Talked with a couple other shareholders have received one.

If anyone has details of this alleged letter, please share.

This means we only have 90 days or less to trade this security??? Also will there be any compensation for the stock holders on record???

I think the Form 15 was a prudent action, Seven, because the SEC has shown no leniency to BK Registrant Filers when they become severely delinquent in their filing obligations to the SEC.

Good move, IMO.

Thanks for posting the Form 15.

APHYQ - Form 15 filed today.

http://ih.advfn.com/p.php?pid=nmona&article=66093225&symbol=APHYQ

APHYQ Have you got any more info yet? Somebody dropped over a million shares yesterday... got the PPS down to .003... Any chance of some recovery here? Or is this just a dead play?

APHYQ - I have not. Been traveling. Planning on reaching out to find out what happened. Not sure if I will get anything more than what has been communicated, and that which has not.

Did you get a chance to talk to Robert to find out what happened and brought on the bankruptcy?

APHYQ - Yet the stock trades up today on decent volume.

APHYQ - I need to get more information. They had a solid business plan, and the debt financing didn't appear to be toxic.

There was just little interest in the retail investment sector, IMO.

I will check out their 8-K later today.

I lost some money on this one, but not enough to be concerned.

I know nothing about Assured Pharmacy, Seven. Were any dilutive (toxic) financings involved or was their debt load too heavy in contrast to earnings? Any other factors?

It is an unpleasant task for me to submit any ticker change with the suffix 'Q' to be added.

I understand your expertise is in pharmaceuticals so you would be the most qualified person to assess Assured Pharmacy's bankruptcy....and I would like to learn.

Regards, Seven.

APHYQ- Surprised that their business model failed. Company had a legit business model.

Another start up bites the dust.

APHY changed to APHYQ: bankruptcy

http://otce.finra.org/DLSymbolNameChanges

APHY - There isn't a chill on this stock Scottrade must have quite an inventory issue.

I just tried to buy and got a chill message from Scottrade

No I didn't. Still waiting for any dip the BxA has quite a gap yet. Hoping for some .12s or .13s

Did you pick some up the other day?

Thank you! I think we could see some nice price action on this one. Better than the other one we are in . I didn't want to post on that board, but yes I think I got the same PM as you did. Didn't put too much into it, was hoping the info was good, but obviously it wasn't. APHY - I'm thinking we should get back up towards the .60 range since that's the price the shares were issued. Might take a little time but I got some .10's yesterday Good luck to you if you are in on this and that other crappy stock we are in!

I saw your post. It's interesting to say the least but I can't find who the new debt holder is. My suspicion is Ironridge because this sounds like the type of company they look for. I'm watching this closely for now. Great find!

APHY NEWS - anyone notice the news this morning. Not sure why its not showing up on ihub.

PLANO, TX--(Marketwired - May 6, 2014) - Assured Pharmacy, Inc. ("Assured Pharmacy" or the "Company") (OTCQB: APHY), a growing provider of pharmacy services to patients and physicians primarily in the treatment of chronic pain, today released the following letter to its shareholders:

Dear Shareholder,

These past several months have given us a chance to review our business and make some changes, which we believe will make Assured Pharmacy a stronger company and award shareholders for the long-term. Management would like to provide an update on our significant progress across a number of areas and our vision for the future. The management team and I are more excited than ever about what lies ahead.

We have strengthened our financial position considerably by bringing in new capital and restructuring our balance sheet. A lead investor provided us with $1.44 million of new capital to date, which enabled us to design and implement a plan to streamline our operations and target near-term profitability. The new capital has been disbursed throughout our operations to meet increasing demand from physicians who wish to have greater precision in the management of their chronic patients. We have successfully restructured a significant amount of our outstanding debt. The holders of the Company's long-term debt, totaling approximately $5.5 million, have agreed to extend the maturity of their debt until 2016. In addition, the holders of the Company's long-term debt, totaling approximately $1.5 million, have converted their debt into common equity at a price of $0.60 per share. As part of the debt extensions and conversions, an aggregate total of approximately $800,000 in accrued interest has been converted into common equity at a price of $0.60 per share. All of these balance sheet adjustments allow us to focus the new capital on meeting the increasing demand for our services resulting in revenue growth.

As described in our most recent annual report filed on Form 10-K, management has decided to concentrate our working capital on the Company's operations and support our two remaining pharmacies with optimal prospects. After analyzing historical financial performance, regulatory costs, current sales prospects, geographic and physical location and strength of existing physician relationships, management elected to close the Gresham and Riverside pharmacies on August 5, 2013 and August 8, 2013, respectively.

Following the closures of the Gresham and Riverside pharmacies, customer demand at both our Kansas City and Seattle pharmacies has consistently increased and is accelerating. Since the restructure of our operations, our revenue per business day from our Kansas City and Seattle pharmacies has increased approximately 130% from approximately $12,500 in revenue per day in July 2013 to approximately $28,700 in revenue per day in March 2014. The key driver behind the revenue growth has been the increase in the number of prescriptions. Since the restructure of our operations, our prescriptions per business day from our Kansas City and Seattle pharmacies has increased approximately 31% from approximately 153 prescriptions per day in July 2013 to approximately 202 prescriptions per day in March 2014. Our prescriptions volume is a lead indicator of revenue growth.

We are focused on reaching profitability in 2014 and believe that concentrating our working capital in our Kansas City and Seattle pharmacies will help us reach that goal. Over the past year, management believes it has proven the success of our business model at our newest location in Kansas City and successfully replicated the model in our Seattle location. We are looking to continue that success and replicate the model in select expansion locations, including Denver and Boston.

The foundation for our plan to increase sales at our existing two pharmacies is based on expanding our outreach program to physicians, including more effectively communicating to them the risk management and service benefits that our business model provides compared to a general pharmacy and increasing our customer retention rate. We believe that increasing our inventory levels and expanding our purchasing capacity with existing and new drug suppliers can strengthen our customer retention rates. Since the majority of our pharmacies' operating expenses are fixed expenses, we expect any increase in revenue to have a positive impact on our consolidated operating results. Management believes that the infrastructure of our existing pharmacies can support an increased prescription production volume by as much as an additional 75% to 100% without incurring any significant additional operating expenses, but there can be no assurances in this regard.

Our longer-term plan remains focused on developing a national footprint as a premier provider of pharmacy services to physicians and patients primarily in the treatment of chronic pain and other chronic medical conditions that require treatment utilizing controlled medications. Prescription drug abuse and diversion have resulted in ever increasing regulations. Our business model provides pharmacy services, which are typically utilized by physicians for the risk management benefits. We have developed and refined what we believe is a unique pharmacy service model for the dispensing of controlled medications that is capable of being scaled into a national chain.

We believe that our current corporate infrastructure can efficiently support up to total of twelve operating pharmacies. Corporate infrastructure includes executive management, centralized support services, accounting, finance, information systems, human resources, payroll and compliance to support each pharmacy's operations. In order to align the costs of our current corporate infrastructure with our scaled back operations, management has implemented cost reduction initiatives including staffing reductions, deferral of senior management compensation and reduced operating costs at our two remaining pharmacies. As a result, we believe that the implementation of our plan to open up to ten additional pharmacies will not require material additional corporate infrastructure. Further, management believes that opening each new pharmacy will have a positive impact on our consolidated operating results within six months from opening of the new pharmacy, but there can be no assurance that such positive results will occur.

The past several months have posed some challenges for the Company that have largely been overcome. With our corporate repositioning predominantly behind us, an experienced management team in place, and significant opportunities on the horizon for our business, we are eager to execute our plans over the next few months.

Please stay tuned for future announcements from Assured Pharmacy. In the meantime, thank you for your ongoing support.

Sincerely,
Robert DelVecchio
Chief Executive Officer
http://finance.yahoo.com/news/assured-pharmacy-issues-shareholder-letter-124500179.html

APHY - This is a SOLID long-term play!

APHY Stock is at $0.60 a share, with their new store openings in the coming months, and the mega fines with CVS and Walgreens, APHY should see tremendous value being added to their stocks.

http://www.usatoday.com/story/news/nation/2013/06/11/walgreens-drug-oxycodone-license-80-million/2412451/

APHY - Seeing more volume on APHY.

APHY is gaining more recognition nationwide from physicians, major chain pharmacies, and investors. I think its value is much higher than it seems.

Retail Pharma Stocks to Move Higher!


http://www.smallcapnetwork.com/Three-Decisions-That-Can-Send-Retail-Pharmacy-and-Pharmaceutical-Stocks-Higher-BIOS-ARNA-VVUS-APHY/s/via/24406/article/view/p/mid/1/id/2/

Affordable Care Act to benefit ASSURED (APHY)

http://beta.fool.com/ykurt/2013/06/17/affordable-care-act-will-benefit-drugstores-treati/37486/


The new store openings will benefit APHY with a shift to positive cash flow.

Company well set for increasing revenue. The company is setting up new store locations and capitalizing on the niche pain med marker--stemming the possibility of patient misuse or abuse. Company is on the forefront of a new shift. APHY is a fine investment at this time.

New Stores Means MORE REVENUE

http://finance.yahoo.com/news/aphy-announces-store-openings-part-144900907.html

Assured is already profiting from its current stores. Every new location means BIG business.

APHY - Assured Pharmacy Hires Hayden IR

Assured Pharmacy, Inc. (QB) (USOTC:APHY)

Today : Wednesday 22 May 2013


PLANO, Texas, May 22, 2013 /PRNewswire/ -- Assured Pharmacy, Inc. (APHY), a leading pharmacy group that specializes in providing prescription medications to sufferers of chronic pain, announced it has engaged Hayden IR, a fifteen-year old, highly recognized, national investor relations firm, to raise its visibility and strengthen its relationships with the investment community.

"Over the past year, we have proven our business model and derived a plan for growth. We recently announced plans to open two additional new pharmacies in Denver and Boston as part of our major expansion strategy. These are important steps as we begin to enter the growth phase for our network of pharmacies focused on the needs of chronic pain patients and the serving physicians," said Robert DelVecchio, the Company's Chief Executive Officer. Mr. DelVecchio continued to say, "we believe it is an appropriate time to retain a national investor relations firm to help us target and expand our investor audience and ensure we are communicating effectively with Wall Street. We look forward to working with the team of professionals at Hayden IR to execute this important goal."

With offices in New York, Phoenix, Minneapolis and San Diego, Hayden IR provides a comprehensive range of investor relations services to a growing list of clients. For more than a decade, Hayden IR has been a recognized leader in driving market recognition and creating sustainable competitive advantages for more than 100 micro- and small-cap companies. Hayden delivers expertise and professionalism in such areas as investor management, relationship building, awareness campaigns, online presence and corporate identity.

Stephen Hart, VP of Capital Markets Advisory, of Hayden IR, added, "Assured Pharmacy represents a compelling opportunity as it has demonstrated landmark success at its Kansas pharmacy over the past 18 months since its opening in late-2011. The Company has a solid foundation of which to replicate as it looks to grow its pharmacy network. The Company generated $14 million of revenue in 2012 and is now embarking on a growth strategy."

Mr. Hart continued to say, "The Company's strategy is to expand to new cities in a very prudent method. Assured Pharmacy evaluates physician demand in targeted expansion cities before it commits. This strategy for growth limits the downside risk of entering a new city or geographic area. Assured Pharmacy believes it has identified and validated new locations for it to be able to double its revenue over the next two years. The team at Hayden IR looks forward to articulating this opportunity to the professional investment community."

About Assured Pharmacy, Inc.
Assured Pharmacy, Inc. is a growing provider of pharmacy services to patients and physicians in the treatment of chronic pain. Through its network of pharmacies, the Company predominantly dispenses highly regulated pain medications to sufferers of chronic pain, while stringently adhering to federal and state reporting requirements for both patients and physicians. The majority of the Company's business is derived from repeat visits from its customer base of physician-referred chronic pain patients. The Company currently has four operating pharmacies which are wholly owned. Learn more about Assured Pharmacy, Inc. at www.AssuredRxServices.com

Forward-Looking Statements
Forward-Looking Statements. This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2011, including but not limited to the discussion under "Risk Factors" therein, which the Company has filed with the SEC and which may be viewed at http://www.sec.gov.

Contact Information
Robert DelVecchio, CEO
rdelvecchio@assuredrxservices.com
972-473-4033

Stephen Hart
Hayden IR
hart@haydenir.com
917-658-7878

SOURCE Assured Pharmacy, Inc.


Copyright 2013 PR Newswire

New Store Openings

http://finance.yahoo.com/news/aphy-announces-store-openings-part-144900907.html

APHY - APHY announces new store openings as part of major expansion

Assured Pharmacy, Inc. (QB) (USOTC:APHY)

Today : Thursday 9 May 2013


FRISCO, Texas, May 9, 2013 /PRNewswire/ -- Assured Pharmacy (APHY:OTC Markets), a leading pharmacy group that specializes in providing prescription medications to sufferers of chronic pain, today announced plans to open two additional new stores in Denver and Boston this summer as part of a major expansion strategy.

Like all Assured Pharmacy stores, the new stores will operate on a compliance-based model to ensure strict control over the safe dispensing and delivery of controlled medications, as well as monitoring patients for all medications they receive. It also ensures compliance with the federal and state regulations and minimizes potential abuses.

Following the model of Assured's highly successful store opening in Kansas last year, the Denver and Boston stores will open with the support of physician groups. With a total cost under $300,000, the Kansas store was EBITDA positive in its sixth full month of operations and has a current annualized revenue run rate of $4 million. Last month, it became the first of Assured's stores to service 1,500 patients in a month, in only its 16th full month of operation, largely due to an expansion in target indications beyond chronic pain to include all chronic controlled medications.

"The landmark success of our Kansas store opening provides a replicable model by which we expect to double our revenues in the next two years," stated Robert DelVecchio, chief executive officer of Assured Pharmacy.

"In addition to the new stores currently under construction, we have identified and pre-marketed four additional locations and have the infrastructure to support a minimum of 12 stores with minimal increase in our corporate cost structure. This aggressive store-opening campaign, coupled with our strategy to accelerate patient intake at existing stores, will allow Assured to significantly increase its national footprint over the next three years."

About Assured Pharmacy, Inc.

Assured Pharmacy, Inc. is a growing provider of pharmacy services to patients and physicians in the treatment of chronic pain. Through its network of pharmacies, the Company predominantly dispenses highly regulated pain mediations to sufferers of chronic pain, while stringently adhering to federal and state reporting requirements for both patients and physicians. The majority of the Company's business is derived from repeat visits from its customer base of physician-referred chronic pain patients. The Company currently has four operating pharmacies which are wholly owned.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this press release. A wide variety of factors that may cause actual results to differ from the forward-looking statements include, but are not limited to, the following: the Company's ability to increase revenue and profits in the current economic climate; the effect of changing economic conditions; lack of sufficient financing for opening new pharmacies; inability to manage growth; and changes in government regulations, controls and similar matters. These cautionary statements should not be construed as exhaustive or as any admission as to the adequacy of the Company's disclosures. The Company cannot predict or determine after the fact what factors would cause actual results to differ materially from those indicated by the forward-looking statements or other statements. The reader should consider statements that include the words "believes", "expects", "anticipates", "intends", "estimates", "plans", "projects", "should", or other expressions that are predictions of or indicate future events or trends, to be uncertain and forward-looking. The Company does not undertake to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

Investor contact:

Robert DelVecchio, CEO
rdelvecchio@assuredrxservices.com
972-673-7394

SOURCE Assured Pharmacy, Inc.


Copyright 2013 PR Newswire

LOOKING INTO THE SPECIALTY PHARMACY SECTOR

http://seekingalpha.com/article/1389981-looking-into-the-specialty-pharmacy-sector

Assured Heading New Regulatory Practices

http://seekingalpha.com/article/1377231-regulation-to-drive-pharmacy-specialization

Specialty Pharmacies Offer Solutions


http://marketplayground.com/2013/04/29/specialty-pharmacies-offer-solutions-also-for-investors-pmc-bios-aphy/

APHY - Will be back well over $1 soon enough.

Another link for the shareholder letter:

http://www.sacbee.com/2013/04/24/5367899/assured-pharmacy-2013-shareholder.html

****** Letter to Shareholders *******


http://www.dailymarkets.com/stock/2013/04/24/assured-pharmacy-2013-shareholder-letter/


FRISCO, Texas, April 24, 2013 /PRNewswire/ — Assured Pharmacy (APHY: OTC Markets), a leading specialty pharmacy group providing prescription medications to sufferers of chronic pain, released its 2013 shareholder letter.

Dear Shareholders,

Every day, prescription pain medications play a role in improving quality of life for the 75 million people who suffer from chronic pain in the US. With the population aging, cancer incidence increasing and the number of surgeries performed growing, that number is expected to increase significantly in the coming years.

The growth of the pain-management market has created opportunities for patients, physicians and the healthcare industry alike, but it has also created challenges: according to the Centers for Disease Control, the illegal use and abuse of controlled medications is an epidemic in the United States.

With the global pain management market expected to reach $60 billion in 2015, the safe and efficient distribution of controlled substances will be crucial to maximizing benefits to patients and physicians, while minimizing the challenges and risks. A pharmacy that specializes in the safe distribution of controlled medications with more than eight years of service to patients, physicians and major drug distributors, Assured Pharmacy is more committed than ever to being the leader in this field.

In order to meet this objective, we are embarking on an aggressive new store-opening campaign for 2013, with the aim of creating a national footprint over the next three years. The low cost of a new store opening, coupled with increased demand for our services, sets the stage for a major expansion, with several near-term milestones on the horizon:

We have already identified six locations for new stores. Using our successful Kansas store opening as a model, we will enlist the support of physician groups prior to opening the new stores to ensure rapid growth and profitability from the start.
We currently have a backlog of patients waiting to begin using Assured that can double the patient base of our existing stores. We are actively raising additional equity capital to accelerate the intake of these new patients.
We are creating strategic relationships with manufacturers to assist them with the distribution of their new products.
Enhancements to our compliance program will ensure our leadership in the safe distribution of controlled medications.
We expect to uplist to NASDAQ or AMEX.
Launch of a long-term investor relations effort will enhance shareholder awareness.
As a small public company we faced many challenges. Last year was no different. We struggled to raise the capital needed for growth. Despite our financial constraints we successfully opened our newest store in Kansas. The Kansas store has set the standard for all new stores and has quickly become our largest and most profitable store, as a result we have begun to adopt many of the model changes in our existing stores. We also expanded our sales target market to include all controlled substances and restructured our terms with our primary wholesaler to significantly improve our gross profit margins. In addition to the operating enhancements, we also uplisted to the OTCQB market, which has given us access to new shareholders and funding opportunities.

Looking back, Assured may have been a little early to the market as a pharmacy specializing in pain management, but we have taken advantage of that time to hone our expertise in the safe and efficient distribution of controlled substances resulting in an efficient, scalable pharmacy model that can be replicated throughout the United States. As the pain management market continues to grow amid tighter regulation and rising concerns about abuse and misuse, Assured remains committed to meeting evermore stringent standards of safety, reliability and compliance — all while providing an exceptional level of service to customers, and value to our shareholders.

Looking ahead, we are excited by the opportunities before us and are grateful to be in a position to capitalize on them, thanks to your support as our shareholders. With an aggressive growth strategy in place and several milestones on the horizon, we look forward to rewarding your support in the year ahead.

Best Regards,

Robert DelVecchio

CEO
Assured Pharmacy, Inc.

http://marketplayground.com/2013/04/22/assured-pharmacy-aphy-a-possible-new-drug-abuse-deterrence-business-model/

WATCH this one! About to take off!

Assured Pharmacy (APHY) is about to explode. Been seeing articles and headlines on the company. Gaining notoriety.


Read this:

http://seekingalpha.com/article/1326841-a-look-at-one-of-the-fastest-growing-industries-in-the-market-and-how-to-benefit

APHY - Lots of potential here in the long-term. Great company and great management.

CEO has a solid business plan and is executing it wisely.

Benefit from one of the FASTEST GROWING industries IN THE MARKET.


http://seekingalpha.com/article/1326841-a-look-at-one-of-the-fastest-growing-industries-in-the-market-and-how-to-benefit

FB page

https://www.facebook.com/AssuredPharmacy